| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |